RxDoctor Payments Data

Jason Springer, MD

Rheumatology · Nashville, TNNPI 1386889806

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,925 of the $2,991 with a category attached, or 64.4%. Amgen accounts for 64.4% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $1,925 and has fallen 94.5% since, to $106 in 2024. That places this record below the midpoint for rheumatology clinicians in TN, where the typical reported total is $5,288.

$2,991in general payments, 2019–2025

Across 6 payments — averaging $498.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • NS Pharma, Inc.$961
  • Janssen Scientific Affairs, LLC$106
$366,599in research payments, 2019–2025

Across 12 payments — averaging $30,550 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$336K
  • NS Pharma, Inc.$30K

What the payments were for

  • Speaking & faculty fees$1,92564%
  • Travel & lodging$66922%
  • Food & beverage$39813%

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen1$1,925
NS Pharma, Inc.4$961
Janssen Scientific Affairs, LLC1$106

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,991 in reported general payments places this provider in the 40th percentile of 127 rheumatology providers in Tennessee.

See all rheumatology providers in Tennessee

Medicare billing

Part B allowed, 2024
$31,681
Medicare patients
143
Services billed
296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab73$553,097
IlarisCanakinumab/Pf12$465,602
Enbrel SureclickEtanercept44$304,523
Cosentyx Sensoready PenSecukinumab21$224,560
BenlystaBelimumab27$129,983
Actemra ActpenTocilizumab18$88,595
Cimzia (2 Pack)Certolizumab Pegol14$78,467
SimponiGolimumab11$68,852
OrenciaAbatacept/Maltose13$53,563
Hydroxychloroquine Sulfate178$6,865
MethotrexateMethotrexate Sodium71$2,597
Leflunomide18$1,642
Colchicine12$1,400
Celecoxib47$1,134
Prednisone157$1,026

Paid to pharmacies, not to this prescriber.

Other rheumatology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →